Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

38%

3 of 8 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

7(77.8%)

Phase 2

2(22.2%)

9Total

Phase 1(7)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02014649Phase 1Terminated

Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza

Role: lead

NCT00657111Phase 1Completed

CS-8958 Single Inhaled Dose in Elderly

Role: lead

NCT01793883Phase 2Completed

Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza

Role: lead

NCT01175226Phase 2Completed

A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

Role: lead

NCT00504907Phase 1Completed

Safety Study of Oral BTA9881 to Treat RSV Infection

Role: lead

NCT02022761Phase 1Completed

Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate TwinCaps® DPI in Adults With Chronic Asthma

Role: lead

NCT00311714Phase 1Completed

Safety, Tolerability and Pharmacokinetic Study of Biota-CS-8958

Role: lead

NCT02204501Phase 1Completed

A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers

Role: lead

NCT00995826Phase 1Completed

Safety, Tolerability and Pharmacokinetic Study of Multiple Doses of CS-8958

Role: lead

All 9 trials loaded